We are a charity and rely on donations

Charity Number: 1117194 (England and Wales)

Registered Company: 06000961

Registered address:
Shift.ms, Platform, New Station Street, LS1 4JB, United Kingdom

London office:
Shift.ms, Somerset House, Strand, West Goods Entrance, London WC2R 1LA, United Kingdom

©2024 Shift.ms

@donnac 

Last reply

donnac

Fingolimod results released...

Novartis have released their data & it looks promising. Relapses were reduced by 54-60% and disease progression by 30-32% versus placebo. This is a once a day capsule immunomodulator that 'parks' your cells that fight infection in yout lymph nodes instead of killing them off like immunosuppressants.
8
@donnac
@donnac
 

For my patients who have been on the trial for 2 years they have found a capsule easier than injections than incorporate into daily life. They have found a slight increase in colds and sniffles but no side effects more serious than that. Fingers crossed for the licence!!!

@donnac
@donnac
 

Well, the initial data looks encouraging and it has proven to be more effective than Avonex and doesn't have the 'flu-like' symptoms that the current DMD's have. Fingolimod reduces the number of lymphocytes (a white blood cell) in your blood stream by storing them in the lymph nodes. Lymphocytes fight infection which is why my patients had a few more sniffles. The advantage to 'parking' your lymphocytes is that when you need them again, say, if you get a seriously severe infection, and the numbers build up within a few days!